|
4. Scope of consolidation
Stevanato Group S.p.A. is the parent company of the Group and it holds, directly and indirectly, interests in the Group’s main operating companies. The Group’s scope of consolidation at December 31, 2022 and 2021 is as follows:
Subsidiaries
The consolidated financial statements of the Group include the following list of company directly or indirectly controlled:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% equity interest |
Name |
|
Segment |
|
Description |
|
Country of incorporation |
|
Type of control |
|
2022 |
|
|
2021 |
Nuova Ompi S.r.l. |
|
Biopharmaceutical |
|
Production of drug containment solutionss and development of integrated solutions for the pharmaceutical industry |
|
Italy |
|
Direct |
|
100% |
|
|
100% |
Spami S.r.l. |
|
Engineering |
|
Production plant and machinery |
|
Italy |
|
Direct |
|
100% |
|
|
100% |
Stevanato Group International a.s. |
|
Holding |
|
Service/Subholding company |
|
Slovakia |
|
Direct |
|
100% |
|
|
100% |
Medical Glass a.s. |
|
Biopharmaceutical |
|
Production of drug containment solutions |
|
Slovakia |
|
Indirect |
|
99.74% |
|
|
99.74% |
Stevanato Group N.A. S. de RL de CV |
|
Biopharmaceutical |
|
Service company |
|
Mexico |
|
Indirect |
|
100% |
|
|
100% |
Ompi N.A. S. de RL de CV |
|
Biopharmaceutical |
|
Production of drug |
|
Mexico |
|
Direct |
|
30.76% |
|
|
30.76% |
|
|
|
|
containment solutions |
|
|
|
Indirect |
|
69.24% |
|
|
69.24% |
Ompi of America inc. |
|
Biopharmaceutical |
|
Sale of drug containment solutions and analytical services |
|
USA |
|
Direct |
|
83.73% |
|
|
0% |
|
|
|
|
|
|
|
|
Indirect |
|
16.27% |
|
|
100% |
Ompi do Brasil I. e C. de |
|
Biopharmaceutical |
|
Production of drug |
|
Brazil |
|
Direct |
|
79% |
|
|
79% |
Em. Far. Ltda |
|
|
|
containment solutions |
|
|
|
Indirect |
|
21% |
|
|
21% |
Innoscan A/S |
|
Engineering |
|
Production plant and machinery |
|
Denmark |
|
Indirect |
|
|
— |
|
|
100% |
Ompi Pharm. Packing Techn. Co. Ltd |
|
Biopharmaceutical |
|
Production of drug containment solutions |
|
China |
|
Indirect |
|
100% |
|
|
100% |
SVM Automatik A/S |
|
Engineering |
|
Production plant and machinery |
|
Denmark |
|
Indirect |
|
100% |
|
|
100% |
Medirio SA |
|
Biopharmaceutical |
|
Research and development |
|
Switzerland |
|
Indirect |
|
100% |
|
|
100% |
Balda Medical Gmbh |
|
Biopharmaceutical |
|
Production of in-vitro diagnostic solutions |
|
Germany |
|
Direct |
|
100% |
|
|
100% |
Balda C. Brewer Inc. |
|
Biopharmaceutical |
|
Production of in-vitro diagnostic solutions |
|
USA |
|
Indirect |
|
100% |
|
|
100% |
Balda Precision Inc. |
|
Biopharmaceutical |
|
Production metal components |
|
USA |
|
Indirect |
|
100% |
|
|
100% |
Ompi of Japan Co., Ltd. |
|
Biopharmaceutical |
|
Sale of drug containment solutions |
|
Japan |
|
Direct |
|
51% |
|
|
51% |
The scope of consolidation as at December 31, 2022 is essentially unchanged compared to December 31, 2021. On December 31, 2022, the extraordinary shareholders' meetings held at the Innoscan A/S and SVM Automatik A/S approved the merger of the non-surviving company Innoscan A/S into the surviving company SVM Automatik A/S. The transaction is effective for accounting purposes as of January 1, 2022.
Non-controlling interests
The non-controlling interests as at December 31, 2022 and 2021 and the net profit attributable to non-controlling interests for the years ended December 31, 2021 and 2022 relate to Ompi of Japan Co., Ltd. and Medical Glass a.s.. For further details refer to Note 36.
|